Title |
Mesenchymal stromal cells to modulate immune reconstitution early post-hematopoietic cell transplantation
|
---|---|
Published in |
BMC Immunology, December 2015
|
DOI | 10.1186/s12865-015-0135-7 |
Pubmed ID | |
Authors |
Elizabeth O. Stenger, Lakshmanan Krishnamurti, Jacques Galipeau |
Abstract |
Mesenchymal stromal cells (MSCs) are multipotent progenitor cells known to modulate the immune system and to promote hematopoiesis. These dual effects make MSCs attractive for use as cellular therapy in hematopoietic cell transplantation (HCT). MSCs can be used peri-HCT or pre-engraftment to modulate immune reconstitution, promoting hematopoietic stem cell (HSC) engraftment and/or preventing graft-versus-host disease (GVHD). Pre-clinical studies have demonstrated that MSCs can potentiate HSC engraftment and prevent GVHD in a variety of animal models. Clinical trials have been small and largely non-randomized but have established safety and early evidence of efficacy, supporting the need for larger randomized trials. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
United Kingdom | 1 | 50% |
Unknown | 1 | 50% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 2 | 100% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
United Kingdom | 1 | 3% |
United States | 1 | 3% |
Unknown | 30 | 94% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Ph. D. Student | 9 | 28% |
Researcher | 6 | 19% |
Student > Bachelor | 4 | 13% |
Student > Postgraduate | 3 | 9% |
Other | 2 | 6% |
Other | 6 | 19% |
Unknown | 2 | 6% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 8 | 25% |
Biochemistry, Genetics and Molecular Biology | 6 | 19% |
Agricultural and Biological Sciences | 6 | 19% |
Pharmacology, Toxicology and Pharmaceutical Science | 2 | 6% |
Immunology and Microbiology | 2 | 6% |
Other | 7 | 22% |
Unknown | 1 | 3% |